Efficacy and safety evaluation of human reovirus type 3 in immunocompetent animals: racine and nonhuman primates.

PubWeight™: 1.11‹?› | Rank: Top 10%

🔗 View Article (PMID 15623640)

Published in Clin Cancer Res on December 15, 2004

Authors

Wen Qing Yang1, Xueqing Lun, Cheryl Ann Palmer, M Elizabeth Wilcox, Huong Muzik, Zhong Qiao Shi, Richard Dyck, Matt Coffey, Brad Thompson, Mark Hamilton, Sandra G Nishikawa, Penny M A Brasher, Kevin Fonseca, David George, N Berry Rewcastle, Randal N Johnston, Doug Stewart, Patrick W K Lee, Donna L Senger, Peter A Forsyth

Author Affiliations

1: Departments of Oncology and Clinical Neurosciences, University of Calgary, and Tom Baker Cancer Centre, Calgary, Alberta, Canada.

Articles citing this

Rat brain tumor models in experimental neuro-oncology: the C6, 9L, T9, RG2, F98, BT4C, RT-2 and CNS-1 gliomas. J Neurooncol (2009) 2.33

Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res (2005) 1.91

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39

Oncolytic virus therapy for glioblastoma multiforme: concepts and candidates. Cancer J (2012) 1.35

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35

Oncolytic viral therapy of malignant glioma. Neurotherapeutics (2009) 1.12

Efficacy and safety/toxicity study of recombinant vaccinia virus JX-594 in two immunocompetent animal models of glioma. Mol Ther (2010) 1.05

Phase 1 clinical trial of intratumoral reovirus infusion for the treatment of recurrent malignant gliomas in adults. Mol Ther (2014) 0.96

Prophylactic alpha interferon treatment increases the therapeutic index of oncolytic vesicular stomatitis virus virotherapy for advanced hepatocellular carcinoma in immune-competent rats. J Virol (2005) 0.95

Oncolytic virotherapy for malignant glioma: translating laboratory insights into clinical practice. Front Oncol (2013) 0.95

Current status of gene therapy for brain tumors. Transl Res (2012) 0.90

Gene therapy trials for the treatment of high-grade gliomas. Gene Ther Mol Biol (2007) 0.88

Adenoviral virotherapy for malignant brain tumors. Expert Opin Biol Ther (2009) 0.88

N-acetylcysteine amide augments the therapeutic effect of neural stem cell-based antiglioma oncolytic virotherapy. Mol Ther (2013) 0.85

Gene therapy-mediated reprogramming tumor infiltrating T cells using IL-2 and inhibiting NF-κB signaling improves the efficacy of immunotherapy in a brain cancer model. Neurotherapeutics (2012) 0.85

EXPLORING THE ANTITUMOR EFFECT OF VIRUS IN MALIGNANT GLIOMA. Drugs Future (2016) 0.84

Clinical development of reovirus for cancer therapy: An oncolytic virus with immune-mediated antitumor activity. World J Methodol (2016) 0.82

HIF-1α downregulation and apoptosis in hypoxic prostate tumor cells infected with oncolytic mammalian orthoreovirus. Oncotarget (2014) 0.82

Unlocking the promise of oncolytic virotherapy in glioma: combination with chemotherapy to enhance efficacy. Ther Deliv (2015) 0.78

Oncolytic Virotherapy for the Treatment of Malignant Glioma. Neurotherapeutics (2017) 0.78

Oncolytic reovirus synergizes with chemotherapeutic agents to promote cell death in canine mammary gland tumor. Can J Vet Res (2016) 0.76

Downregulation of key regulatory proteins in androgen dependent prostate tumor cells by oncolytic reovirus. Virology (2015) 0.75

Articles by these authors

Accurate whole human genome sequencing using reversible terminator chemistry. Nature (2008) 90.20

Effect of influenza vaccination of children on infection rates in Hutterite communities: a randomized trial. JAMA (2010) 4.21

Association between the 2008-09 seasonal influenza vaccine and pandemic H1N1 illness during Spring-Summer 2009: four observational studies from Canada. PLoS Med (2010) 3.85

Aldehyde dehydrogenase: its role as a cancer stem cell marker comes down to the specific isoform. Cell Cycle (2011) 2.80

Aldehyde dehydrogenase activity of breast cancer stem cells is primarily due to isoform ALDH1A3 and its expression is predictive of metastasis. Stem Cells (2011) 2.75

Component-specific effectiveness of trivalent influenza vaccine as monitored through a sentinel surveillance network in Canada, 2006-2007. J Infect Dis (2009) 2.59

Effectiveness of AS03 adjuvanted pandemic H1N1 vaccine: case-control evaluation based on sentinel surveillance system in Canada, autumn 2009. BMJ (2011) 2.50

Effects of school closure on incidence of pandemic influenza in Alberta, Canada. Ann Intern Med (2012) 2.42

Sequential phases of cortical specification involve Neurogenin-dependent and -independent pathways. EMBO J (2004) 2.30

Swine outbreak of pandemic influenza A virus on a Canadian research farm supports human-to-swine transmission. Clin Infect Dis (2011) 2.28

A phase I study of intravenous oncolytic reovirus type 3 Dearing in patients with advanced cancer. Clin Cancer Res (2008) 2.18

Integrating mortality and morbidity outcomes: using quality-adjusted life years in critical care trials. Am J Respir Crit Care Med (2012) 2.15

Randomized trial of high-dose chemotherapy with autologous peripheral-blood stem-cell support compared with standard-dose chemotherapy in women with metastatic breast cancer: NCIC MA.16. J Clin Oncol (2007) 2.15

Obstetric and perinatal outcomes in singleton pregnancies resulting from IVF/ICSI: a systematic review and meta-analysis. Hum Reprod Update (2012) 2.05

Prophylactic anticonvulsants in patients with brain tumour. Can J Neurol Sci (2003) 1.99

Proliferation of human glioblastoma stem cells occurs independently of exogenous mitogens. Stem Cells (2009) 1.96

Recruitment maneuvers for acute lung injury: a systematic review. Am J Respir Crit Care Med (2008) 1.91

Cyclophosphamide facilitates antitumor efficacy against subcutaneous tumors following intravenous delivery of reovirus. Clin Cancer Res (2008) 1.91

Subversion of autophagy by Kaposi's sarcoma-associated herpesvirus impairs oncogene-induced senescence. Cell Host Microbe (2012) 1.82

A phase I trial of intratumoral administration of reovirus in patients with histologically confirmed recurrent malignant gliomas. Mol Ther (2008) 1.81

Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties. Neuro Oncol (2009) 1.80

Obstetric and perinatal outcomes in singleton pregnancies resulting from the transfer of frozen thawed versus fresh embryos generated through in vitro fertilization treatment: a systematic review and meta-analysis. Fertil Steril (2012) 1.78

Design and validation of real-time reverse transcription-PCR assays for detection of pandemic (H1N1) 2009 virus. J Clin Microbiol (2009) 1.76

Oncolytic reovirus against ovarian and colon cancer. Cancer Res (2002) 1.73

Reovirus activates human dendritic cells to promote innate antitumor immunity. J Immunol (2008) 1.70

Comparison of the Luminex xTAG respiratory viral panel with xTAG respiratory viral panel fast for diagnosis of respiratory virus infections. J Clin Microbiol (2011) 1.68

ATM deficiency sensitizes mantle cell lymphoma cells to poly(ADP-ribose) polymerase-1 inhibitors. Mol Cancer Ther (2010) 1.67

Phase I/II trial of carboplatin and paclitaxel chemotherapy in combination with intravenous oncolytic reovirus in patients with advanced malignancies. Clin Cancer Res (2012) 1.67

p21Cip1/WAF1 mediates cyclin B1 degradation in response to DNA damage. Cell Cycle (2009) 1.60

Systemic reovirus therapy of metastatic cancer in immune-competent mice. Cancer Res (2003) 1.59

A sentinel platform to evaluate influenza vaccine effectiveness and new variant circulation, Canada 2010-2011 season. Clin Infect Dis (2012) 1.58

The evolving genome of Salmonella enterica serovar Pullorum. J Bacteriol (2002) 1.57

Enhanced in vitro and in vivo cytotoxicity of combined reovirus and radiotherapy. Clin Cancer Res (2008) 1.56

Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. Proc Natl Acad Sci U S A (2004) 1.53

Efficacy of systemically administered oncolytic vaccinia virotherapy for malignant gliomas is enhanced by combination therapy with rapamycin or cyclophosphamide. Clin Cancer Res (2009) 1.53

Loss of protein inhibitors of activated STAT-3 expression in glioblastoma multiforme tumors: implications for STAT-3 activation and gene expression. Clin Cancer Res (2008) 1.52

Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res (2007) 1.50

Elevated membrane-type matrix metalloproteinases in gliomas revealed by profiling proteases and inhibitors in human cancer cells. Mol Cancer Res (2003) 1.50

Synergistic effects of oncolytic reovirus and cisplatin chemotherapy in murine malignant melanoma. Clin Cancer Res (2009) 1.50

Proteolytic disassembly is a critical determinant for reovirus oncolysis. Mol Ther (2007) 1.48

Cell carriage, delivery, and selective replication of an oncolytic virus in tumor in patients. Sci Transl Med (2012) 1.46

Reovirus oncolysis of human breast cancer. Hum Gene Ther (2002) 1.45

Longitudinal study of influenza molecular viral shedding in Hutterite communities. J Infect Dis (2012) 1.45

Biogenesis of p53 involves cotranslational dimerization of monomers and posttranslational dimerization of dimers. Implications on the dominant negative effect. J Biol Chem (2002) 1.44

Enhanced cytotoxicity of PARP inhibition in mantle cell lymphoma harbouring mutations in both ATM and p53. EMBO Mol Med (2012) 1.44

A phase I study of the combination of intravenous reovirus type 3 Dearing and gemcitabine in patients with advanced cancer. Clin Cancer Res (2010) 1.42

A framework for biobank sustainability. Biopreserv Biobank (2014) 1.41

The p75 neurotrophin receptor is a central regulator of glioma invasion. PLoS Biol (2007) 1.40

Vesicular stomatitis virus oncolysis is potentiated by impairing mTORC1-dependent type I IFN production. Proc Natl Acad Sci U S A (2010) 1.39

Open endarterectomy of the SPT segment: an experience. Ann Vasc Surg (2007) 1.39

Effects of intravenously administered recombinant vesicular stomatitis virus (VSV(deltaM51)) on multifocal and invasive gliomas. J Natl Cancer Inst (2006) 1.36

Two-stage phase I dose-escalation study of intratumoral reovirus type 3 dearing and palliative radiotherapy in patients with advanced cancers. Clin Cancer Res (2010) 1.35

Clinical review: Goal-directed therapy-what is the evidence in surgical patients? The effect on different risk groups. Crit Care (2013) 1.35

Gene expression profiling reveals a highly specialized genetic program of plasma cells. Blood (2003) 1.34

Neutrophils recruited to sites of infection protect from virus challenge by releasing neutrophil extracellular traps. Cell Host Microbe (2013) 1.33

Goal-directed therapy in high-risk surgical patients: a 15-year follow-up study. Intensive Care Med (2010) 1.32

Salmonella paratyphi C: genetic divergence from Salmonella choleraesuis and pathogenic convergence with Salmonella typhi. PLoS One (2009) 1.30

Chk2 is dispensable for p53-mediated G1 arrest but is required for a latent p53-mediated apoptotic response. Proc Natl Acad Sci U S A (2002) 1.28

Reovirus therapy of lymphoid malignancies. Blood (2002) 1.28

Full-genome analysis of avian influenza A(H5N1) virus from a human, North America, 2013. Emerg Infect Dis (2014) 1.27

Engraftment assessment in human and mouse liver tissue after sex-mismatched liver cell transplantation by real-time quantitative PCR for Y chromosome sequences. Liver Transpl (2002) 1.27

Oncolytic reovirus effectively targets breast cancer stem cells. Mol Ther (2009) 1.27

Interaction of the extracellular domain of the epidermal growth factor receptor with gangliosides. J Biol Chem (2002) 1.26

Blunted rostral anterior cingulate response during a simplified decoding task of negative emotional facial expressions in alcoholic patients. Alcohol Clin Exp Res (2007) 1.26

Toxicity from chemoradiotherapy in older patients with glioblastoma multiforme. J Neurooncol (2008) 1.24

Population-based study of pseudoprogression after chemoradiotherapy in GBM. Can J Neurol Sci (2009) 1.24

Oncolytic virus-initiated protective immunity against prostate cancer. Mol Ther (2011) 1.24

Influenza A/subtype and B/lineage effectiveness estimates for the 2011-2012 trivalent vaccine: cross-season and cross-lineage protection with unchanged vaccine. J Infect Dis (2014) 1.23

Antiangiogenic cancer therapy combined with oncolytic virotherapy leads to regression of established tumors in mice. J Clin Invest (2010) 1.22

Alcohol advertising and youth. Alcohol Clin Exp Res (2002) 1.21

DNA damage-induced apoptosis requires the DNA-dependent protein kinase, and is mediated by the latent population of p53. EMBO J (2002) 1.21

Effect of female age on the diagnostic categories of infertility. Hum Reprod (2008) 1.21

Phase II trial of intravenous administration of Reolysin(®) (Reovirus Serotype-3-dearing Strain) in patients with metastatic melanoma. Mol Ther (2012) 1.20

Oncogenic Ras promotes reovirus spread by suppressing IFN-beta production through negative regulation of RIG-I signaling. Cancer Res (2010) 1.19

The DNA-dependent protein kinase (DNA-PK): More than just a case of making ends meet? Cell Cycle (2010) 1.17

Improved systemic delivery of oncolytic reovirus to established tumors using preconditioning with cyclophosphamide-mediated Treg modulation and interleukin-2. Clin Cancer Res (2009) 1.17

Oncolytic viral therapy for prostate cancer: efficacy of reovirus as a biological therapeutic. Cancer Res (2010) 1.16